Arcus Biosciences, Inc. (RCUS)
NYSEHealth CareBiotechnologySnapshot 2026-09-09
$28.49-1.96%
Close 2026-09-09 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Arcus Biosciences aims to grow revenue from $50M to $65M in 2026. It maintains a strategic partnership with Gilead Sciences. Management is focused on reducing operating losses despite recent challenges. The stock has gained 36% over 63 days, showing market interest.
Revenue fell 39% year-over-year in Q1 2026 to $17M. Operating losses increased to $134M in Q1 from $114M in Q4 2025. The company remains unprofitable with negative EPS and faces elevated risk. Analysts expect nearly 47% revenue decline next year.
The price is about 3% above our fair value near $29, below the Street median of $35. The market expects a steep 47% revenue decline, which may be too pessimistic if turnaround efforts succeed.
Breaks if: Operating loss worsens beyond -$134 million over next 4 quarters
Breaks if: Revenue falls below $50 million in FY26
Partnership with Gilead ends or materially weakens
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is focused on advancing its therapies in kidney cancer and immunology, but it is currently loss-making and faces elevated risks in a challenging market environment.
The market seems to have priced in a significant expectations gap, suggesting that investors may not fully believe in the company's ability to execute its plans. The valuation shows a premium compared to peers, indicating that the market expects a re-rating based on future performance.
Management has set clear priorities for advancing its therapies, although recent financial performance has been mixed. The company showed a recovery in revenue in the latest quarter, but it remains to be seen if this trend will continue amid industry volatility.
The thesis hinges on the company's ability to meet its clinical milestones and the overall performance of the healthcare sector. Key triggers include guidance updates and the performance of sector bellwethers, which could influence investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no current threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, RCUS's success will depend on its execution of clinical trials and market conditions. Not investment advice.